258 related articles for article (PubMed ID: 12737068)
21. [Prevention of community-acquired respiratory syncytial virus infections in premature infants: cost-benefit evaluation in the Finistère Department].
Jacquemot L; Catelin C; Dobrzynski M; de Parscau L; Sizun J
Arch Pediatr; 2002 Feb; 9(2):219-21. PubMed ID: 11915507
[No Abstract] [Full Text] [Related]
22. [Experience of palivizumab in prophylaxis of respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia].
Aliamovskaia GA; Keshinian ES
Vestn Ross Akad Med Nauk; 2012; (12):30, 32-4. PubMed ID: 23530423
[TBL] [Abstract][Full Text] [Related]
23. [Humanized respiratory syncytial virus monoclonal antibody].
Tsutsumi H
Nihon Rinsho; 2002 Mar; 60(3):487-91. PubMed ID: 11904963
[TBL] [Abstract][Full Text] [Related]
24. Palivizumab. An example of indication creep.
Isaacs D
BMJ; 2009 Jul; 339():b2724. PubMed ID: 19581330
[No Abstract] [Full Text] [Related]
25. Palivizumab.
Gupta D; Gupta P
Indian Pediatr; 2001 Nov; 38(11):1265-9. PubMed ID: 11721066
[No Abstract] [Full Text] [Related]
26. Prevention and treatment of respiratory syncytial virus infections (for advances in pediatric infectious diseases).
DeVincenzo J
Adv Pediatr Infect Dis; 1997; 13():1-47. PubMed ID: 9544306
[No Abstract] [Full Text] [Related]
27. Palivizumab in infants with gestational age < or = 28 weeks and bronchopulmonary dysplasia.
Parmigiani S; Ubaldi A; Capuano C; Massinissa Magini G; Bianchi ME
Acta Biomed Ateneo Parmense; 2001; 72(5-6):109-13. PubMed ID: 12233268
[TBL] [Abstract][Full Text] [Related]
28. [Current news about epidemiology of syncytial respiratory virus infection].
Palumbo E
Recenti Prog Med; 2008 May; 99(5):237-9. PubMed ID: 18581965
[TBL] [Abstract][Full Text] [Related]
29. Palivizumab: new indication. Moderate reduction in hospitalisation rate.
Prescrire Int; 2004 Dec; 13(74):213-6. PubMed ID: 15612142
[TBL] [Abstract][Full Text] [Related]
30. [Palivizumab--a monoclonal antibody for passive immunoprophylaxis of respiratory syncytial virus infections].
Scholz H
Z Geburtshilfe Neonatol; 2000; 204(3):120-2. PubMed ID: 10909169
[TBL] [Abstract][Full Text] [Related]
31. Immunoprophylaxis for respiratory syncytial virus.
Sánchez PJ
Pediatr Infect Dis J; 2002 May; 21(5):473-8. PubMed ID: 12150195
[No Abstract] [Full Text] [Related]
32. [Methodological aspects of economic evaluation in pediatrics: illustration by RSV infection prophylaxis in the French setting].
Hascoet JM; Fagnani F; Charlemagne A; Vieux R; Rozé JC; Bendjenana H
Arch Pediatr; 2008 Dec; 15(12):1739-48. PubMed ID: 18990549
[TBL] [Abstract][Full Text] [Related]
33. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.
Carbonell-Estrany X; Simões EA; Dagan R; Hall CB; Harris B; Hultquist M; Connor EM; Losonsky GA;
Pediatrics; 2010 Jan; 125(1):e35-51. PubMed ID: 20008423
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
Elhassan NO; Sorbero ME; Hall CB; Stevens TP; Dick AW
Arch Pediatr Adolesc Med; 2006 Oct; 160(10):1070-6. PubMed ID: 17018467
[TBL] [Abstract][Full Text] [Related]
35. Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks.
Resch B; Gusenleitner W; Müller WD; Haas J
Eur J Clin Microbiol Infect Dis; 2006 Feb; 25(2):120-2. PubMed ID: 16491302
[No Abstract] [Full Text] [Related]
36. A community health concern: respiratory syncytial virus and children.
Miller S
J Pediatr Nurs; 2010 Dec; 25(6):551-4. PubMed ID: 21035019
[TBL] [Abstract][Full Text] [Related]
37. Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia.
Grimaldi M; Gouyon B; Sagot P; Quantin C; Huet F; Gouyon JB;
Pediatr Pulmonol; 2007 Mar; 42(3):189-92. PubMed ID: 17243184
[TBL] [Abstract][Full Text] [Related]
38. Cost minimisation of RSV prevention with palivizumab.
Wills S; Simpson JH; Coutts J
Arch Dis Child; 2006 Aug; 91(8):717. PubMed ID: 16861501
[No Abstract] [Full Text] [Related]
39. The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine.
Krilov LR; Weiner LB; Yogev R; Fergie J; Katz BZ; Henrickson KJ; Welliver RC
Pediatrics; 2009 Dec; 124(6):1682-4. PubMed ID: 19948634
[No Abstract] [Full Text] [Related]
40. Appropriate use of palivizumb (Synagis).
Graham LM; Lesnick B
Pediatr Pulmonol Suppl; 2004; 26():156-7. PubMed ID: 15029637
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
